The U.S. Food and Drug Administration approved Gilead Sciences’ once-daily oral combination pill Bixlenvo for the treatment of adults whose HIV infection has been reduced to very low levels, the company announced on August 27. The drug combines two existing HIV medicines: bictegravir, a key component of Gilead’s widely used treatment Biktarvy, and lenacapavir, a capsid inhibitor marketed as Sunlenca for treatment and Yeztugo for prevention.
The approval targets an estimated 5% or more of U.S. adults living with HIV who are on complex treatment regimens or seeking alternative options despite having their virus suppressed. Bixlenvo is the first single-tablet regimen available for this population, according to Gilead.
The list price of Bixlenvo is $4,595 for a 30-day supply before discounts or rebates, aligning with other daily single-tablet HIV treatments. Gilead stated that uninsured patients may qualify for free medication through its patient assistance program, while those with insurance could access co-pay support via another savings program.
How Bixlenvo Works
Bictegravir, the primary active ingredient, is a well-established HIV drug with a high barrier to resistance, making it a cornerstone in HIV treatment. Lenacapavir, a first-in-class capsid inhibitor, disrupts the virus’s protective shell to prevent its multiplication. Together, the combination aims to simplify care for patients who may struggle with existing regimens.
Patient Access and Clinical Rationale
Dr. Jared Baeten, Gilead’s head of clinical development and virology, emphasized that Bixlenvo fulfills an unmet need by offering a consolidated treatment option for patients on complex regimens or those seeking new alternatives. The approval reflects Gilead’s long-term strategy to expand HIV treatment and prevention options, with lenacapavir playing a central role in this effort.
HIV remains a chronic condition with no effective cure, though antiretroviral therapies like Bixlenvo can suppress the virus to undetectable levels, preventing progression to AIDS. The FDA’s decision provides an additional tool for clinicians and patients navigating long-term HIV management.